Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection

Article Abstract:

Subcutaneous injections of interleukin-2 in addition to zidovudine and didanosine appear to be effective in the early stages of HIV infection. Interleukin-2 stimulates the production of CD4 and CD8 T cells and also stimulates the immune system in other ways. Researchers asked 12 patients in the early stages of HIV infection to inject themselves with interleukin-2 four times a month for six months. The patients also took zidovudine and didanosine regularly. At the end of six months, CD4 T cell counts had risen and remained high after interleukin-2 was discontinued. Viral counts were lower and remained so after interleukin-2 was discontinued.

Zidovudine, Interleukin-2

---

Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers

Article Abstract:

Delavirdine appears to inhibit metabolism of indinavir, but does not alter absorption of the drug, when they are administered together. Delavirdine is a non-nucleoside reverse transcriptase inhibitor and indinavir is a protease inhibitor, both used in the treatment of HIV. Researchers gave the drugs to 14 healthy volunteers to determine patterns of absorption and drug interaction. Delviridine slightly lengthened the time required for indinavir levels in the blood to fall. When the drugs are used together, the dosage or dosing frequency of indinavir may be reduced.

Indinavir, Dosage and administration, Antiviral agents, Drug interactions, Reverse transcriptase inhibitors

---

HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine

Article Abstract:

Didanosine does not appear to prevent drug resistance in HIV when given in combination with delavirdine. Delavirdine belongs to the class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs). Researchers used genetic testing to see if HIV isolated from the blood of 9 HIV-infected patients became resistant to delavirdine when given in combination with didanosine, which is also called ddI. Within 4 to 10 weeks of treatment, 5 of the patients had HIV isolates that had acquired a mutation at codon 181 that made the virus resistant to delavirdine.

HIV (Viruses), HIV, Drug resistance in microorganisms, Microbial drug resistance

Similar abstracts:

• Abstracts: Pharmacokinetics of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine
• Abstracts: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
• Abstracts: Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection: a randomized, double-blind, placebo-controlled trial
• Abstracts: Amniotic fluid interleukin-10 concentrations increase through pregnancy and are elevated in patients with preterm labor associated with intrauterine infection
• Abstracts: A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.